<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558857</url>
  </required_header>
  <id_info>
    <org_study_id>065.5</org_study_id>
    <nct_id>NCT00558857</nct_id>
  </id_info>
  <brief_title>Dynamic Substrate Mapping (DSM) for Ischemic VT</brief_title>
  <acronym>DSM</acronym>
  <official_title>Clinical Feasibility of Using Dynamic Substrate Mapping to Guide Ablation of Ischemic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized study to determine the feasibility of using a new&#xD;
      technique called Dynamic Substrate Mapping (DSM) to help guide the treatment of ischemic&#xD;
      ventricular tachycardia (IVT). We hypothesize that DSM will lead to simpler, more effective&#xD;
      ablation of IVT. Results from this study will be used to determine if further clinical&#xD;
      investigation is warranted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Ischemic Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>DSM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment using DSM to guide ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Substrate Mapping-guided ablation</intervention_name>
    <description>Radiofrequency ablation</description>
    <arm_group_label>DSM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have an ICD or CRT-D device&#xD;
&#xD;
          -  Had at least 3 documented device therapies to treat VT over last 3 months&#xD;
&#xD;
          -  Clinical VT is confirmed or suspected to be of ischemic origin&#xD;
&#xD;
          -  Scheduled for VT ablation procedure&#xD;
&#xD;
          -  LVEF &gt; or = 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate AAD washout (amiodarone should be maintained at current dose)&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Active ischemia&#xD;
&#xD;
          -  Cardiac surgery within prior 2 months&#xD;
&#xD;
          -  Evidence of infection&#xD;
&#xD;
          -  Prosthetic mitral or aortic valve or mitral/aortic valvular heart disease requiring&#xD;
             surgical intervention&#xD;
&#xD;
          -  History of embolic event&#xD;
&#xD;
          -  Myocardial infarction within prior 6 weeks&#xD;
&#xD;
          -  Enrolled in another study&#xD;
&#xD;
          -  Recurrent sepsis or otherwise not a candidate for catheterization&#xD;
&#xD;
          -  Hypercoagulable state or inability to tolerate heparin therapy during procedure&#xD;
&#xD;
          -  Has had an atriotomy or ventriculotomy within prior 4 months&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Class IV NYHA classification&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Callans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital at the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2007</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <name_title>Donna Godejohn</name_title>
    <organization>St. Jude Medical</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

